Persistent antihypertensive effect of aliskiren is accompanied by reduced proteinuria and normalization of glomerular area in Ren-2 transgenic rats

American Journal of Physiology - Renal Physiology

Volumn 299, Issue 4, 2010, Pages

  Rakušan, Dan ^a   Kujal, Petr ^a   Kramer, Herbert J ^b   Huskov́a, Zuzana ^a   Vaňourková, Zdeňka ^a   Vernerová, Zdenka ^a   Mrázová, Iveta ^a   Thumová, Monika ^a   Červenka, Luděk ^a   Vaněčková, Ivana ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

^b UNIVERSITY OF BONN   (Germany)

Author keywords

Blood pressure; Direct renin inhibition; Glomerular size; Hypertension; Losartan; Morphometry; Washout period

Indexed keywords

ALISKIREN; ANGIOTENSIN II; LOSARTAN; AMIDE; ANTIHYPERTENSIVE AGENT; FUMARIC ACID DERIVATIVE; REN2 PROTEIN, RAT; RENIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE MONITORING; DRUG EFFECT; DRUG WITHDRAWAL; HEART VENTRICLE HYPERTROPHY; HETEROZYGOTE; HYPERTENSION; MALE; NONHUMAN; OSMOTIC MINIPUMP; PRIORITY JOURNAL; PROTEINURIA; RAT; TELEMETRY; TRANSGENIC RAT; TREATMENT DURATION; ANIMAL; BLOOD; BLOOD PRESSURE; CARDIOMEGALY; COMPARATIVE STUDY; DISEASE MODEL; DRUG EFFECTS; GENETICS; GLOMERULUS; HEART RATE; METABOLISM; PATHOLOGY; TIME;

AMIDES; ANGIOTENSIN II; ANIMALS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CARDIOMEGALY; DISEASE MODELS, ANIMAL; FUMARATES; HEART RATE; HYPERTENSION; KIDNEY GLOMERULUS; LOSARTAN; MALE; PROTEINURIA; RATS; RATS, TRANSGENIC; RENIN; TIME FACTORS;

EID: 77958006134     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00259.2010     Document Type: Article

References (38)

1. Batenburg WW, de Bruin RJ, van Gool JM, Muller DN, Bader M, Nguyen G, Danser AH. Aliskiren-binding increases the half life of renin and prorenin in rat aortic vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 28: 1151-1157, 2008.
2. Bohlender J, Fukamizu A, Lippoldt A, Nomura T, Dietz R, Menard J, Murakami K, Luft FC, Ganten D. High human renin hypertension in transgenic rats. Hypertension 29: 428-434, 1997. (Pubitemid 27074079)
3. Bramlage P, Schindler C. Differences in pharmacology and their translation into differences in clinical efficacy - a comparison of the renin angiotensin blocking agents irbesartan and losartan. Expert Opin Pharmacother 11: 521-535, 2010.
4. Cheng JW. Aliskiren: renin inhibitor for hypertension management. Clin Ther 30: 31-47, 2008.
5. 1-receptor blocker therapy ameliorate target-organ damage in rats harbouring human renin and angiotensinogen genes. J Renin Angiotensin Aldosterone Syst 8: 81-84, 2007.
6. Feldman DL. New insights into the renoprotective actions of the renin inhibitor aliskiren in experimental renal disease. Hypertens Res 33: 279-287, 2010.
7. Feldman DL, Jin L, Xuan H, Contrepas A, Zhou Y, Webb RL, Mueller DN, Feldt S, Cumin F, Maniara W, Persohn E, Schuetz H, Jan Danser AH, Nguyen G. Effects of aliskiren on blood pressure, albuminuria, and (pro)renin receptor expression in diabetic TG(mRen- 2)27 rats. Hypertension 52: 130-136, 2008.
8. Feldman DL, Persohn E, Schuetz H, Jin L. Renal localization of renin inhibitor aliskiren. J Clin Hypertens 8: 80-81, 2006.
9. Funke-Kaiser H, Zollmann FS, Schefe JH, Unger T. Signal transduction of the (pro)renin receptor as a novel therapeutic target for preventing end-organ damage. Hypertens Res 33: 98-104, 2010.
10. Halimi JM, Asmar R, Ribstein J. Optimal nephroprotection: use, misuse and misconceptions about blockade of the renin-angiotensin system. Lessons from the ONTARGET and other recent trials. Diabetes Metab 35: 425-430, 2009.
11. Huskova Z, Kramer HJ, Thumova M, Vanourkova Z, Burgelova M, Teplan V, Maly J, Cervenka L. Effects of anesthesia on plasma and kidney ANG II levels in normotensive and ANG II-dependent hypertensive rats. Kidney Blood Press Res 29: 74-83, 2006.
12. Ichihara A, Sakoda M, Kurauchi-Mito A, Narita T, Kinouchi K, Murohashi-Bokuda K, Itoh H. Possible roles of human (pro)renin receptor suggested by recent clinical and experimental findings. Hypertens Res 33: 177-180, 2010.
13. Ijpelaar DH, Schulz A, Koop K, Schlesener M, Bruijn JA, Kerjaschki D, Kreutz R, de Heer E. Glomerular hypertrophy precedes albuminuria and segmental loss of podoplanin in podocytes in Munich-Wistar-Fromter rats. Am J Physiol Renal Physiol 294: F758-F767, 2008.
14. Kelly DJ, Zhang Y, Moe G, Naik G, Gilbert RE. Aliskiren, a novel renin inhibitor, is renoprotective in a model of advanced diabetic nephropathy in rats. Diabetologia 50: 2398-2404, 2007.
15. 1 receptor blockade in hypertensive Ren-2 transgenic rats. J Hypertens 22: 819-825, 2004.
16. Kriz W, Elger M, Mundel P, Lemley KV. Structure-stabilizing forces in the glomerular tuft. J Am Soc Nephrol 5: 1731-1739, 1995.
17. Krop M, Garrelds IM, de Bruin RJ, van Gool JM, Fisher ND, Hollenberg NK, Jan Danser AH. Aliskiren accumulates in renin secretory granules and binds plasma prorenin. Hypertension 52: 1076-1083, 2008.
18. Kurtz TW, Griffin KA, Bidani AK, Davisson RL, Hall JE. Recommendations for blood pressure measurement in animals: summary of an AHA scientific statement from the Council on High Blood Pressure Research, Professional and Public Education Subcommittee. Arterioscler Thromb Vasc Biol 25: 478-479, 2005.
19. Lambers Heerspink HJ, Perkovic V, de Zeeuw D. Renal and cardioprotective effects of direct renin inhibition: a systematic literature review. J Hypertens 27: 2321-2331, 2009.
20. Lee MA, Bohm M, Kim S, Bachmann S, Bachmann J, Bader M, Ganten D. Differential gene expression of renin and angiotensinogen in the TGR(mREN-2)27 transgenic rat. Hypertension 25: 570-580, 1995.
21. Mitchell KD, Jacinto SM, Mullins JJ. Proximal tubular fluid, kidney, and plasma levels of angiotensin II in hypertensive ren-2 transgenic rats. Am J Physiol Renal Physiol 273: F246-F253, 1997.
22. Mullins JJ, Peters J, Ganten D. Fulminant hypertension in transgenic rats harbouring the mouse Ren-2 gene. Nature 344: 541-544, 1990.
23. Nagase M, Shibata S, Yoshida S, Nagase T, Gotoda T, Fujita T. Podocyte injury underlies the glomerulopathy of Dahl salt-hypertensive rats and is reversed by aldosterone blocker. Hypertension 47: 1084-1093, 2006.
24. Oh BH, Mitchell J, Herron JR, Chung J, Khan M, Keefe DL. Aliskiren, an oral renin inhibitor, provides dose-dependent efficacy and sustained 24-hour blood pressure control in patients with hypertension. J Am Coll Cardiol 49: 1157-1163, 2007.
25. Opocensky M, Kramer HJ, Backer A, Vernerova Z, Eis V, Cervenka L, Certikova C, Tesar V, Vaneckova I. Late-onset endothelin-A receptor blockade reduces podocyte injury in homozygous Ren-2 rats despite severe hypertension. Hypertension 48: 965-971, 2006.
26. Parving HH, Persson F, Lewis JB, Lewis EJ, Hollenberg NK. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med 358: 2433-2446, 2008.
27. Persson F, Rossing P, Schjoedt KJ, Juhl T, Tarnow L, Stehouwer CD, Schalkwijk C, Boomsma F, Frandsen E, Parving HH. Time course of the antiproteinuric and antihypertensive effects of direct renin inhibition in type 2 diabetes. Kidney Int 73: 1419-1425, 2008.
28. Pilz B, Shagdarsuren E, Wellner M, Fiebeler A, Dechend R, Gratze P, Meiners S, Feldman DL, Webb RL, Garrelds IM, Jan Danser AH, Luft FC, Muller DN. Aliskiren, a human renin inhibitor, ameliorates cardiac and renal damage in double-transgenic rats. Hypertension 46: 569-576, 2005.
29. Pimenta E, Oparil S. Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors. Vasc Health Risk Manag 5: 453-463, 2009.
30. Riccioni G, Vitulano N, D'Orazio N, Bellocci F. Aliskiren, the first approved renin inhibitor: clinical application and safety in the treatment of hypertension. Adv Ther 26: 700-710, 2009.
31. Saito T, Sumithran E, Glasgow EF, Atkins RC. The enhancement of aminonucleoside nephrosis by the co-administration of protamine. Kidney Int 32: 691-699, 1987.
32. Schnermann J, Briggs JP. Function of the juxtaglomerular apparatus: control of glomerular hemodynamics and renin secretion. In: The Kidney: Physiology and Pathophysiology, edited by Seldin DW, Giebisch G. Philadelphia, PA: Lippincott Williams & Wilkins, 2000.
33. Vaňourková Z, Kramer HJ, Husková Z, Červenka L, Vaněčková I. Despite similar reduction of blood pressure and renal ANG II and ET-1 levels aliskiren but not losartan normalizes albuminuria in hypertensive Ren-2 rats. Physiol Res 59: 339-345, 2010.
34. Vernerova Z, Kramer HJ, Backer A, Cervenka L, Opocensky M, Huskova Z, Vanourkova Z, Eis V, Chabova VC, Tesar V, Maly J, Vaneckova I. Late-onset endothelin receptor blockade in hypertensive heterozygous REN-2 transgenic rats. Vascul Pharmacol 48: 165-173, 2008.
35. 1R blockade on myocardial remodeling in the transgenic Ren2 rat. Am J Physiol Endocrinol Metab 295: E103-E109, 2008.
36. Whaley-Connell AT, Chowdhury NA, Hayden MR, Stump CS, Habibi J, Wiedmeyer CE, Gallagher PE, Tallant EA, Cooper SA, Link CD, Ferrario C, Sowers JR. Oxidative stress and glomerular filtration barrier injury: role of the renin-angiotensin system in the Ren2 transgenic rat. Am J Physiol Renal Physiol 291: F1308-F1314, 2006.
37. 1R blockade on glomerular filtration barrier injury in the transgenic Ren2 rat. Am J Physiol Renal Physiol 298: F655-F661, 2010.
38. Zicha J, Kunes J. Ontogenetic aspects of hypertension development: analysis in the rat. Physiol Rev 79: 1227-1282, 1999.